This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
earnings-estimates: Archive
NextNRG Inc. (NXXT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
NextNRG Inc. (NXXT) delivered earnings and revenue surprises of +33.33% and +18.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
NXXTPositive Net Change CSIQNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Afya (AFYA) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Afya (AFYA) delivered earnings and revenue surprises of -2.17% and -0.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
AFYANegative Net Change DLTHNo Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
RCM Technologies, Inc. (RCMT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
RCM Technologies (RCMT) delivered earnings and revenue surprises of +51.85% and +16.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
RCMTPositive Net Change KFYPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Blaize Holdings, Inc. (BZAI) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Blaize Holdings, Inc. (BZAI) delivered earnings and revenue surprises of -16.67% and -4.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
BZAIPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of +3.92% and -46.47%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
BTAIPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
VIQ SOLUTIONS (VQSSF) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
VIQ SOLUTIONS (VQSSF) delivered earnings and revenue surprises of +300.00% and +125.88%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
VQSSFNo Net Change TOMZPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MediciNova (MNOV) delivered earnings and revenue surprises of +16.67% and +205.63%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
MNOVNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
MacroGenics (MGNX) delivered earnings and revenue surprises of +32.50% and -25.45%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
MGNXPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Jefferson Capital, Inc. (JCAP) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Jefferson Capital, Inc. (JCAP) delivered earnings and revenue surprises of +6.35% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
JCAPPositive Net Change HSDTPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of +8.33% and +31.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
CAMPNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank